ATRICURE INC.

Atricure Inc. specializes in the design, manufacture, and supply of advanced surgical ablation systems and consumable medical devices used in minimally invasive cardiac and thoracic procedures. Their core capabilities center on radiofrequency and cryoablation technologies, delivering precision energy-based solutions for treating atrial fibrillation and other arrhythmias. The company demonstrates deep technical expertise in sterile, single-use surgical instruments, catheter-based delivery systems, and integrated ablation platforms optimized for clinical reliability and procedural consistency. Atricure’s products are engineered to meet stringent FDA and ISO 13485 standards, with a focus on reproducible tissue lesion formation and real-time procedural feedback—key differentiators in the interventional electrophysiology market. The company maintains a consistent relationship with the Department of Veterans Affairs, supplying critical ablation consumables and systems to VA medical centers for cardiac care delivery. It also supports the Department of Health and Human Services, including emergency procurement of specialized cryosurgical probes for clinical use. These engagements reflect a trusted supplier relationship focused on mission-critical surgical inventory and rapid-response medical device deployment. Atricure’s primary industry focus lies in surgical appliance and supplies manufacturing (NAICS 339113) and surgical and medical instrument manufacturing (NAICS 339112), positioning it as a niche provider in electrophysiology-focused device ecosystems. The firm serves the hospital-based procedural market with FDA-cleared, single-use ablation products that reduce variability and enhance procedural outcomes. As a 2L entity headquartered in Mason, Ohio, Atricure operates as a mid-sized manufacturer with no federal certifications on record. Its geographic presence is centered in the U.S., with a focused government market footprint aligned with veteran and public health service delivery networks.